Marko Stojanovic

MD. I run clinical trials. Building a 30-year dividend growth portfolio. Pharma & biotech through a clinician's eyes. NFA.

[Marko Stojanovic @100janovicpharm]

As promised, the full Article is here.

I've spent years running clinical trials. I own zero pharma stocks.

Phases, patent cliffs, windfalls, politics, and the quiet AI revolution in drug discovery. Plus the few I'd consider 👇 https://t.co/Ta1aMUzVFk

[Marko Stojanovic @100janovicpharm]

@BacklogAlpha My favorite

[Marko Stojanovic @100janovicpharm]

$SCHD hit a new all-time high this week.

The ETF people called "dead money" for years.

No AI story. No capex debate.
Just companies that keep raising their dividends.

Still boring. Still buying.

[Marko Stojanovic @100janovicpharm]

@Raj_Invests Boring is moat 🏰

[Marko Stojanovic @100janovicpharm]

@SCHDETF

[Marko Stojanovic @100janovicpharm]

@amktparticipant Same here, SCHD is anchor!

[Marko Stojanovic @100janovicpharm]

@joshkaineallen Good choice man!

[Marko Stojanovic @100janovicpharm]

@amktparticipant It was a good week.

[Marko Stojanovic @100janovicpharm]

@BacklogAlpha There is another option - Google

[Marko Stojanovic @100janovicpharm]

@dividendology Cheaper on P/E. More expensive vs bonds.

Earnings yield (1 / P/E):
2022: 4.7% vs 1.6% Treasury → stocks paid 3.1% more
2026: 5.3% vs 4.9% Treasury → stocks pay 0.4% more

In 2022 you got paid well to take stock risk. Today you barely do.

[Marko Stojanovic @100janovicpharm]

@Compound_Kid_ Doing something scary: looking at the Nasdaq's Friday performance.

[Marko Stojanovic @100janovicpharm]

@PenneyInvests Costume named - Best time to buy

[Marko Stojanovic @100janovicpharm]

@jpinvests98 I will do the same on Monday!

[Marko Stojanovic @100janovicpharm]

@ConvictionStack 4 more. You got this!

[Marko Stojanovic @100janovicpharm]

@Bearlovesbull As a Microsoft holder, I like this setup. Microsoft gets the capacity without carrying the full capex, and IREN carries the build-out risk. That $3B gap is IREN's problem, not Microsoft's.

[Marko Stojanovic @100janovicpharm]

We have entered -FCF territory. Meta (and others) are now spending massive amounts on AI infrastructure without clear proof of when it will turn into meaningful cash flow. This raises the risk. The core ad business is still very strong, but this is no longer the low-risk investment it was 2–3 years ago.

[Marko Stojanovic @100janovicpharm]

@slava_invests 💯 right. Most people your age only realize this later. The time you have now is really your biggest advantage — just keep investing and learning without big mistakes. That’s the formula.

[Marko Stojanovic @100janovicpharm]

@BrnMeetsWlth 💯

[Marko Stojanovic @100janovicpharm]

@BacklogAlpha The spending on infrastructure scares me…